Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Company Overview

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

Key Stats

• Today's Range: $20.41 to $21.27
• 50-Day Range: $19.13 to $21.26
• 52-Week Range: $19.05 to $26.58
• Volume: 1.48 million shs
• Average Volume: 1.58 million shs
• Market Capitalization: $2.51 billion
• P/E Ratio: 12.44
• Dividend Yield: N/A
• Price Target: $33.20
• Consensus Rating: Buy

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

Catalyst Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 41st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Catalyst Pharmaceuticals has a consensus price target of $33.20, representing about 61.7% upside from its current price of $20.53.

Amount of Analyst Coverage

Catalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 12.11%

Earnings Growth

Earnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Catalyst Pharmaceuticals is 12.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Catalyst Pharmaceuticals is 12.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.07.

Price to Earnings Growth Ratio

Catalyst Pharmaceuticals has a PEG Ratio of 0.85. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Catalyst Pharmaceuticals has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.87% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently increased by 11.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Catalyst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Catalyst Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.99

Percentage of Shares Shorted

7.87% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Catalyst Pharmaceuticals has recently increased by 11.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.97

News Sentiment

Catalyst Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Catalyst Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

28 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

11 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,927,241.00 in company stock.

Percentage Held by Insiders

10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CPRX Stock Analysis - Frequently Asked Questions

How have CPRX shares performed this year?

Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of the year. Since then, CPRX stock has decreased by 1.6% and is now trading at $20.53.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Monday, September, 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. The biopharmaceutical company earned $53.11 million during the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a trailing twelve-month return on equity of 40.78%.

Is Catalyst Pharmaceuticals doing a stock buyback?

Catalyst Pharmaceuticals' board authorized a stock buyback plan on Wednesday, October 1st 2025, which permits the company to repurchase $200,000,000 in shares, according to EventVestor. This means that the company could buy up to 8.3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Who are Catalyst Pharmaceuticals' major shareholders?

Top institutional shareholders of Catalyst Pharmaceuticals include Pacer Advisors Inc. (0.51%), Voya Investment Management LLC (0.36%), Wedge Capital Management L L P NC (0.12%) and Assenagon Asset Management S.A. (0.12%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Brian Elsbernd, Richard J Daly, Philip H Coelho, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper.
View institutional ownership trends.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 9/25/2023
• Today: 10/17/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CPRX
• CIK: 1369568
• Web: www.catalystpharma.com
• Phone: (305) 420-3200
• Fax: 305-529-0933
• Employees: 80
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Catalyst Pharmaceuticals: $33.20
• High Price Target: $36.00
• Low Price Target: $30.00
• Potential Upside/Downside: +61.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.65
• Trailing P/E Ratio: 12.44
• Forward P/E Ratio: 10.81
• P/E Growth: 0.85
• Net Income: $163.89 million
• Net Margins: 37.36%
• Pretax Margin: 48.70%
• Return on Equity: 40.78%
• Return on Assets: 35.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.71
• Quick Ratio: 6.55

Sales & Book Value

• Annual Sales: $491.73 million
• Price / Sales: 5.11
• Cash Flow: $2.36 per share
• Price / Cash Flow: 8.69
• Book Value: $6.10 per share
• Price / Book: 3.37

Miscellaneous

• Outstanding Shares: 122,390,000
• Free Float: 109,662,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 0.79